AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nannini, E. C.
Right arrow Articles by Murray, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nannini, E. C.
Right arrow Articles by Murray, B. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 529-532, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.529-532.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activity of Tigecycline (GAR-936), a Novel Glycylcycline, against Enterococci in the Mouse Peritonitis Model

Esteban C. Nannini,1,2 Suresh R. Pai,1,2 Kavindra V. Singh,1,2 and Barbara E. Murray1,2,3*

Center for the Study of Emerging and Re-Emerging Pathogens,1 Division of Infectious Diseases, Department of Internal Medicine,2 Department of Microbiology and Molecular Genetics, The University of Texas Medical School, Houston, Texas3

Received 11 July 2002/ Returned for modification 17 September 2002/ Accepted 10 November 2002


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peritonitis against three Enterococcus faecalis and four Enterococcus faecium isolates with different susceptibilities to vancomycin and tetracyclines, all of which were inhibited by <=0.125 µg of tigecycline/ml. Using a single subcutaneous dose, tigecycline displayed a protective effect (50% protective dose, <=5.7 mg/kg of body weight) against all strains tested, including two with Tn925 (from the Tn916 family), which contains the Tet(M) tetracycline resistance determinant, as well as VanA and VanB strains. As expected, tetracycline and minocycline were ineffective against the isolates carrying Tn925.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Enterococci have long been known to cause endocarditis, urinary tract infections, intraabdominal and pelvic infections, intravascular catheter-related bacteremia, bacteremia from unknown origin, soft tissue infections, and neonatal sepsis and meningitis (4, 8). The interest in this organism has increased in recent years, particularly because of the rising incidence of vancomycin-resistant enterococci (VRE), with a major impact in nosocomial infections, where enterococci have been ranked as the third most common cause of bloodstream infections (5). Among enterococcal strains causing nosocomial infections in intensive care units during the year 2000, 26.3% were VRE, representing a 31% increase in the vancomycin resistance rate compared with the mean rate of vancomycin resistance observed in the previous 5 years, as reported by the Centers for Disease Control and Prevention (1). This situation has led to a search for antienterococcal agents with new mechanisms of action or to reformulation of older ones.

The efficacy of tetracyclines has been impaired by the widespread existence of genes conferring resistance to them, probably secondary to the long history of tetracycline use in humans, in field crops and fruit trees, and as food additives for growth promotion in animals (14). In 1988, a new tetracycline with modifications in the minocycline hydrophobic domain conferring activity against tetracycline-resistant organisms was developed, and this eventually led to the synthesis of novel structures called glycylcyclines. The glycylcycline tigecycline (GAR-936) is a 9-t-butylglycylamido derivative of minocycline; this new agent inhibits protein synthesis even in the presence of Tet(M)-protected ribosomes, probably due to its tight binding (11). Tigecycline has shown in vitro activity against many gram-positive organisms, including vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium, regardless of the susceptibility pattern to tetracyclines (3). The aim of this study was to evaluate the in vivo activity of this new agent against various E. faecalis and E. faecium strains, including tetracycline- and vancomycin-resistant ones, in the mouse peritonitis model.

(This work was presented in part at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 16 to 19 December 2001.)


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Organisms. Three E. faecalis isolates used in this study were OG1RF (ATCC 47077), a well-known plasmid-free isolate (9); V583, a vanB and erm(B) clinical isolate (15); and INY1200 (OG1RF::Tn925) (Tn925 is a conjugative transposon from the Tn916 family of transposons [13]) which carries the tet(M) gene encoding tetracycline-minocycline resistance (18). The four E. faecium isolates were TX5034, a VanA type of VRE strain resistant also to erythromycin and streptomycin; TX5037 (TX5034::Tn925), a transconjugant of TX5034 and INY1200, carrying the Tet(M) determinant; TX0016 (DO), a tetracycline- and erythromycin-resistant endocarditis isolate (2) (partial sequence available at http://www.hgsc.bcm.tmc.edu/microbial/Efaecium/index.html); and TX2465, another clinical isolate carrying the vanA gene cluster, from an oncologic patient with bacteremia.

Antibiotics. Tigecycline in powder form was obtained from Wyeth Research, Pearl River, N.Y. Other antibiotics used were tetracycline hydrochloride, minocycline, vancomycin hydrochloride, erythromycin, and ampicillin sodium salt and were obtained from Sigma, St. Louis, Mo. Quinupristin-dalfopristin was obtained from Aventis Pharma, Croix-de-Berny, France.

In vitro susceptibility testing. The MICs of each antimicrobial agent were determined by the agar dilution method using Mueller-Hilton agar II (Becton Dickinson and Company, Cockeysville, Md.) and following the National Committee for Clinical Laboratory Standards guidelines (10). E. faecalis ATCC 29212 and Staphylococcus aureus ATCC 29213 strains were used for quality control.

In vivo efficacy model. Female, 4- to 6-week-old, outbred ICR mice (Harlan Sprague Dawley, Houston, Tex.) with a mean weight between 20 and 25 g were used as previously described (16, 17). Each dosing group was composed of six animals. For the bacterial inoculation, the different strains of enterococci were grown on brain heart infusion (BHI) agar (Difco Laboratories, Detroit, Mich.) plates, then inoculated in BHI broth, and incubated at 37°C overnight. Mice were injected intraperitoneally with 1 ml of the solution containing the infecting enterococcal strain in 12.5% sterile rat fecal extract, resulting in an inoculum of about 10 times the minimum lethal dose (16). Antibiotics were given subcutaneously as a single dose immediately after the intraperitoneal injection. Based on previous observation of the time course of disease, mice infected with E. faecalis were monitored for 96 h, and those infected with E. faecium were monitored for 120 h. The 50% lethal dose and the 50% protective dose (PD50) were determined by the method described by Reed and Muench (12). Preapproved guidelines of the Animal Welfare Committee of the University of Texas Health Science Center at Houston were followed throughout the animal experiments. Bacteria were recovered from the spleens of dead mice and saved for phenotypic comparison and/or pulsed-field gel electrophoresis.


   RESULTS AND DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
The E. faecalis and E. faecium strains used in this study were all inhibited by <=0.125 µg of tigecycline/ml (Table 1); the MIC values obtained were not influenced by the tetracycline or vancomycin susceptibility pattern of the specific isolate.


View this table:
[in this window]
[in a new window]
  		TABLE 1. MICs and PD50s after a single subcutaneous dose of several antibiotics for three E. faecalis and four E. faecium strains

 
Table 1 displays the MICs and PD50s for the three E. faecalis and four E. faecium isolates tested, and Fig. 1 shows two dose-response curves. PD50 values from previous experiments done in our laboratory under different conditions were included for ampicillin and vancomycin (single subcutaneous dose) against OG1RF and TX2465 and for quinupristin-dalfopristin (single intravenous dose) against TX0016 and TX2465, which were previously reported (17). None of the mice in the drug control groups (where only the antibiotic is given) died, and none of the mice in the infection control groups (where mice are infected and no antimicrobial agent is given) survived.



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 1. Survival and dose-response curves for mice intraperitoneally infected with wild-type OG1RF and a tetracycline-resistant derivative. Therapy was given subcutaneously immediately after intraperitoneal injection of bacteria. (A) OG1RF, E. faecalis strain sensitive to tetracycline; (B) INY1200 (OG1RF::Tn925), an OG1RF derivative carrying the Tet(M) tetracycline resistance determinant.

 
Both tetracycline and tigecycline had protective effects (PD50 <= 6 mg/kg) against the tetracycline-susceptible E. faecalis strain OG1RF (ATCC 47077) (Fig. 1A), although the PD50 value for tigecycline was approximately 10 times lower than the PD50 obtained with tetracycline. Against the E. faecalis strain INY1200 (OG1RF::Tn925) (Fig. 1B), tetracycline and minocycline did not decrease mouse lethality, even when doses up to 200 mg/kg of body weight were administered; tigecycline, on the other hand, had a low PD50 value (1.9 mg/kg), similar to that obtained against the parental tetracycline-susceptible strain OG1RF. For E. faecalis V583, tigecycline and minocycline displayed protection against this strain. Among the E. faecium isolates tested, tigecycline and minocycline were effective against the VanA-type strain TX5034. Mice infected with the derivative TX5037 (TX5034::Tn925), carrying the Tet(M) resistance determinant, were effectively protected by tigecycline (PD50, 3.6 mg/kg), while tetracycline was inactive (PD50, >200 mg/kg). When the tetracycline-resistant E. faecium clinical isolate TX0016 was tested, minocycline showed no protective effect, vancomycin was moderately effective (PD50 = 16 mg/kg), and tigecycline displayed the lowest PD50 value (5.7 mg/kg). Against the E. faecium strain TX2465, another VanA type of isolate, tigecycline displayed a slightly lower PD50 value (5.5 mg/kg) than that obtained with minocycline (9.3 mg/kg).

In a recent study (6), tigecycline MICs were determined against 1,203 clinical isolates by broth microdilution methods. The tigecycline MICs at which 90% of isolates were inhibited were <=0.25 µg/ml and 0.12 µg/ml for 100 vancomycin-susceptible and vancomycin-resistant E. faecalis and E. faecium strains and for 10 Enterococcus casseliflavus and Entercoccus gallinarum (genotype vanC) strains, respectively. In the same study, all minocycline-resistant enterococci (4 E. faecalis, 13 E. faecium, and 1 E. hirae isolate) had tigecycline MICs of <=0.25 µg/ml. Another study (3) compared the in vitro activities of tigecycline with those of doxycycline, minocycline, and tetracycline against 527 gram-positive clinical isolates. One third of the enterococci (including several strains of E. faecalis and E. faecium with VanA and VanB types of glycopeptide resistance) were resistant to minocycline and doxycycline, and 44% were resistant to tetracycline; however, all were inhibited by tigecycline at <=2 µg/ml demonstrating, again, that tigecycline retains its activity against enterococci resistant to tetracyclines as a class. In other studies in animals, tigecycline produced a statistically significant bacterial count reduction compared to untreated animals against vancomycin-susceptible and vancomycin-resistant E. faecalis isolates and a VanA-type E. faecium strain in a rat and rabbit model of endocarditis, respectively (7) (A. Lefort, M. Lafaurie, A. Saleh-Mghir, L. Garry, M. C. Peker, D. Le Guludec, C. Carbon, and B. Fantin, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 415, 1999).

In summary, the new glycylcycline tigecycline showed good potency in vitro and in vivo in a mouse peritonitis model against several E. faecalis and E. faecium strains, including tetracycline-resistant strains, suggesting that this may be an attractive agent for the treatment of enterococcal infections and that further studies in humans may be warranted.


   ACKNOWLEDGMENTS
 
This study was supported by a grant from Wyeth Research.


   FOOTNOTES
 
* Corresponding author. Mailing address: Center for the Study of Emerging and Re-emerging Pathogens, University of Texas Medical School —Houston, 6431 Fannin, 1.728 JFB, Houston, TX 77030. Phone: (713) 500-6745. Fax: (713) 500-5495. E-mail: bem.asst{at}uth.tmc.edu. Back


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Anonymous. 2001. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-June 2001, issued August 2001. Am. J. Infect. Control 29:404-421.[CrossRef][Medline]
  2. Arduino, R. C., K. Jacques-Palaz, B. E. Murray, and R. M. Rakita. 1994. Resistance of Enterococcus faecium to neutrophil-mediated phagocytosis. Infect. Immun. 62:5587-5594.[Abstract/Free Full Text]
  3. Boucher, H. W., C. B. Wennersten, and G. M. Eliopoulos. 2000. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob. Agents Chemother. 44:2225-2229.[Abstract/Free Full Text]
  4. Das, I., and J. Gray. 1998. Enterococcal bacteremia in children: a review of seventy-five episodes in a pediatric hospital. Pediatr. Infect. Dis. J. 17:1154-1158.[CrossRef][Medline]
  5. Edmond, M. B., S. E. Wallace, D. K. McClish, M. A. Pfaller, R. N. Jones, and R. P. Wenzel. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244.[Medline]
  6. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936, tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.[CrossRef][Medline]
  7. Murphy, T. M., J. M. Deitz, P. J. Petersen, S. M. Mikels, and W. J. Weiss. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.[Abstract/Free Full Text]
  8. Murray, B. E. 1990. The life and times of the enterococcus. Clin. Microbiol. Rev. 3:46-65.[Abstract/Free Full Text]
  9. Murray, B. E., K. V. Singh, R. P. Ross, J. D. Heath, G. M. Dunny, and G. M. Weinstock. 1993. Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function. J. Bacteriol. 175:5216-5223.[Abstract/Free Full Text]
  10. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard, NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  11. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1994. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Agents Chemother. 38:1658-1660.[Abstract/Free Full Text]
  12. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
  13. Rice, L. B. 1998. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants. Antimicrob. Agents Chemother. 42:1871-1877.[Free Full Text]
  14. Roberts, M. C. 1996. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol. Rev. 19:1-24.[CrossRef][Medline]
  15. Sahm, D. F., J. Kissinger, M. S. Gilmore, P. R. Murray, R. Mulder, J. Solliday, and B. Clarke. 1989. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 33:1588-1591.[Abstract/Free Full Text]
  16. Singh, K. V., X. Qin, G. M. Weinstock, and B. E. Murray. 1998. Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. J. Infect. Dis. 178:1416-1420.[CrossRef][Medline]
  17. Singh, K. V., K. K. Zscheck, and B. E. Murray. 2000. Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model. Antimicrob. Agents Chemother. 44:3434-3437.[Abstract/Free Full Text]
  18. Torres, O. R., R. Z. Korman, S. A. Zahler, and G. M. Dunny. 1991. The conjugative transposon Tn925: enhancement of conjugal transfer by tetracycline in Enterococcus faecalis and mobilization of chromosomal genes in Bacillus subtilis and E. faecalis. Mol. Gen. Genet. 225:395-400.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, February 2003, p. 529-532, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.529-532.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nannini, E. C.
Right arrow Articles by Murray, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nannini, E. C.
Right arrow Articles by Murray, B. E.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS